GlobeNewsWire
03 Nov 2025, 21:30 UTC · 51w ago
Verdict
Headline takes no side. We score PLX −0.40 across two claims — moderately bearish.
−0.40moderately bearish
More negative than 78% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Chiesi and Protalix are seeking a re-examination from the EMA after receiving a negative opinion on the every-four-week (E4W) dosing regimen for Elfabrio.
More negative than 87% of claims this week
The currently approved every-two-week (E2W) dosing regimen for Elfabrio remains in effect in the EU.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 40% of claims this week
Which stocks this story touches
More negative than 78% of ticker scores this week
The company received a negative opinion from the EMA regarding a proposed alternative dosing regimen for Elfabrio.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Insider
17h ago
+8.4%
Price is moving against the score
$2.59 vs $2.39 close before publication (Nov 3) · not market-adjusted
PLX chart →
